Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Lilly is building an oncology franchise with the same speed and conviction it used to dominate GLP-1s. The Kelonia deal is the third major acquisition Lilly has announced in 2026: Orna Therapeutics for $2.4B (in vivo CAR-T for autoimmune, February), Centessa Pharmaceuticals for $7.8B (narcolepsy, March), and now Kelonia for up to $7B (in vivo CAR-T for myeloma, today). That is approximately $17.2B in total deal value in under three months. The strategic logic is explicit: Lilly EVP Jacob Van Naarden said these deals are "all part of Lilly's plan to grow beyond the GLP-1 drugs for obesity and diabetes that Lilly is best known for." The Kelonia deal is particularly notable because the company nearly ran out of cash three times and had raised only $60M over five years. Venrock, which incubated the company, shared the original investment memo and slide deck after the deal was announced. The in vivo CAR-T thesis, administering gene therapy via a single infusion without cell harvesting, manufacturing, or lymphodepletion chemotherapy, is the next frontier in cell therapy. Lilly now owns two of the leading platforms in the space. Meanwhile, today is the biggest day at AACR 2026. Revolution Medicines presents combination daraxonrasib data in first-line pancreatic cancer and zoldonrasib data in NSCLC. Both presentations will define the next phase of the RAS oncology conversation. 👉 Read Full Analysis

Lilly Acquires Kelonia Therapeutics for Up to $7B to Lead the In Vivo CAR-T Race LLY

What Happened: Eli Lilly announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage Boston-based biotech developing in vivo CAR-T cell therapies. Kelonia shareholders will receive up to $7B in cash: $3.25B upfront and subsequent payments upon achievement of clinical, regulatory, and commercial milestones. Close expected H2 2026. The Wall Street Journal first reported the deal was imminent on Sunday evening.

The Technology: Kelonia's proprietary in vivo gene placement system (iGPS) uses engineered lentiviral-based particles designed to selectively enter T-cells inside a patient's body and reprogram them to attack cancer. Unlike current ex vivo CAR-T therapies (Yescarta, Abecma, Carvykti), which require cell harvesting, lab manufacturing, lymphodepletion chemotherapy, and reinfusion, Kelonia's approach involves a single intravenous infusion. No cell removal. No manufacturing wait time. No lymphodepletion chemo.

The Lead Asset: KLN-1010 is a potentially first-in-class lentiviral in vivo anti-BCMA CAR-T therapy in Phase 1 for relapsed/refractory multiple myeloma. Early clinical data were presented in a plenary session at ASH 2025. STAT reported that Kelonia nearly ran out of cash three times and had raised only $60M over its five-year history. Venrock, which incubated the company (originally called Elcano Therapeutics), shared its original investment memo and pitch deck publicly following the deal announcement.

Lilly's 2026 Deal Spree: This is Lilly's third major acquisition of the year:

Total: approximately $17.2B in announced deal value in under three months.

Executive Impact: Lilly EVP Jacob Van Naarden called KLN-1010's early data "highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform." The "platform" point matters. iGPS has potential applicability beyond oncology, including autoimmune disease, which is where Orna's in vivo CAR-T technology is focused. Together, Kelonia and Orna give Lilly two distinct in vivo CAR-T platforms spanning both cancer and autoimmune indications. Lilly is making a bet that in vivo CAR-T will eventually replace ex vivo CAR-T as the standard approach. If that thesis is right, Lilly is building a franchise that could rival Gilead's Yescarta/Arcellx position and BMS's Abecma/Breyanzi business.

👉 Read Full Analysis

Current CAR-T therapies are ex vivo: harvest the patient's T-cells, ship them to a manufacturing facility, engineer them over 2 to 4 weeks, then reinfuse. The process works. BMS's Abecma and Breyanzi, Gilead's Yescarta, and J&J's Carvykti have demonstrated durable responses in blood cancers. But the logistics are a barrier to scale. Manufacturing costs run $300,000 to $500,000 per patient. Wait times can extend beyond a month. Vein-to-vein time is measured in weeks. And lymphodepletion chemotherapy carries its own risks.

In vivo CAR-T eliminates most of these barriers. A single intravenous infusion delivers engineered viral particles that enter the patient's T-cells and reprogram them inside the body. No cell harvesting. No manufacturing facility. No lymphodepletion. If the approach works at scale, it could reduce the cost by an order of magnitude and make CAR-T therapy accessible to a far larger patient population.

Lilly now owns two leading in vivo CAR-T platforms:

Different viral/RNA delivery systems, different disease targets, but the same thesis: in vivo is the future of cell therapy.

The risk: in vivo CAR-T is early stage. No in vivo CAR-T therapy has been approved. The field faces questions about durability (will in vivo-generated CAR-T cells persist?), targeting specificity (will the viral particles only enter T-cells?), and manufacturing consistency (can the viral particles be manufactured at commercial scale?). Lilly is paying $3.25B upfront for a Phase 1 asset with early data and a company that raised $60M total. That is an extraordinary premium on promise.

Lilly has deployed approximately $17.2B in M&A in under three months:

Plus the $2.75B Insilico Medicine AI drug discovery deal from late March. That brings the running total above $18B.

Lilly can afford it. The company is generating record revenue driven by Mounjaro, Zepbound, and Verzenio, and Foundayo is now launching. The balance sheet supports continued M&A. But the pace raises a strategic question: is Lilly diversifying wisely or buying too fast? Three separate oncology/cell therapy/narcolepsy/AI deals in quick succession means three separate integration efforts running in parallel. Execution risk is real, even for a company with Lilly's resources.

Daraxonrasib + chemo in 1L PDAC (mini-symposium): The Phase 1/2 data will show whether adding daraxonrasib to front-line chemotherapy improves response rates and survival versus chemo alone in untreated patients. In September 2025, Revolution shared initial results from a small cohort showing the combination was "highly encouraging." Today's data will be from a larger dataset. The key metrics: overall response rate, disease control rate, duration of response, and safety/tolerability of the combination.

Zoldonrasib in KRAS G12D NSCLC (plenary): This is the first detailed clinical look at Revolution's G12D-selective inhibitor in lung cancer. KRAS G12D mutations are found in approximately 15% of NSCLC patients. If zoldonrasib shows meaningful single-agent activity, it opens a second major indication beyond pancreatic cancer and validates the breadth of Revolution's RAS(ON) platform.

🎯 Catalyst Calendar: April 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →